Breast Cancer Awareness Month is a magical time that brings out the child in each of us. You can keep your Santa Claus and your Tooth Fairy, I believe in the warm and fuzzy feeling of breast cancer awareness.
Data from the CLEOPATRA trial show that pertuzumab adds nearly 16 months to median survival times when used with trastuzumab and chemo in HER2-positive breast cancer, according to final results presented at the ESMO 2014 Congress.
Much of the existing research into the phenomenon commonly referred to as “chemobrain” has been descriptive, and we know enough now to identify some patients at risk for cognitive changes after a diagnosis of cancer.
Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.
More than 90% of women about to undergo a mammography were unable to accurately quantify their risk for breast cancer, either over- or underestimating their risk, according to the results of a large-scale survey presented at the ASCO Breast Cancer Symposium 2013.
Expert radiologists were able to screen magnetic resonance images and rule out breast cancer diagnosis with a negative predictive value of about 99% using an abridged breast MRI protocol in a single-center study presented Saturday at the ASCO Breast Cancer Symposium 2013.
In this Circling Back feature, authors of the review article “Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Long Enough?” discuss some of the especially interesting points made in the commentaries.
A recent prospective trial showed sentinel lymph node surgery has a clinically significant high false negative rate in breast cancer patients with node-positive disease receiving neoadjuvant chemotherapy. In this interview we discuss surgical techniques that detect breast cancer in lymph nodes.